Orosomucoid 1 promotes epirubicin resistance in breast cancer by upregulating the expression of matrix metalloproteinases 2 and 9

References

• Fahad Ullah M. Breast cancer: current perspectives on the disease status. Adv Exp Med Biol. 2019;1152:51–64.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Fuchs HE, et al. Cancer Statistics, 2021. CA Cancer J Clin. 2021 Jan;71(1):7–33.
   PubMed Web of Science ®Google Scholar
• Zheng S, Bai JQ, Li J, et al. The pathologic characteristics of breast cancer in China and its shift during 1999-2008: a national-wide multicenter cross-sectional image over 10 years. Int J Cancer. 2012 Dec 1;131(11):2622–2631.
   PubMed Web of Science ®Google Scholar
• DeSantis CE, Ma J, Goding Sauer A, et al. Breast cancer statistics, 2017, racial disparity in mortality by state. CA Cancer J Clin. 2017 Nov;67(6):439–448.
   PubMed Web of Science ®Google Scholar
• Haydu LE, Scolyer RA, Lo S, et al. Conditional survival: an assessment of the prognosis of patients at time points after initial diagnosis and treatment of locoregional melanoma metastasis. J Clin Oncol. 2017 May 20;35(15):1721–1729.
   PubMed Web of Science ®Google Scholar
• Li J, Guan X, Fan Z, et al. Non-invasive biomarkers for early detection of breast cancer. Cancers (Basel). 2020 Sep 27;12(10):2767.
   PubMed Web of Science ®Google Scholar
• The Lancet. Breast cancer targeted therapy: successes and challenges. Lancet. 2017 Jun 17;389(10087):2350.
   Web of Science ®Google Scholar
• Gu G, Dustin D, Fuqua SA. Targeted therapy for breast cancer and molecular mechanisms of resistance to treatment. Curr Opin Pharmacol. 2016 Dec;31:97–103.
   PubMed Web of Science ®Google Scholar
• Nakhjavani M, Hardingham JE, Palethorpe HM, et al. Druggable molecular targets for the treatment of triple negative breast cancer. J Breast Cancer. 2019 Sep 2;22(3):341–361.
   PubMed Web of Science ®Google Scholar
• Gammans RE, Mayol RF, LaBudde JA. Metabolism and disposition of buspirone. Am J Med. 1986 Mar 31;80(3):41–51.
   PubMedGoogle Scholar
• Yuasa I, Weidinger S, Umetsu K, et al. Orosomucoid system: 17 additional orosomucoid variants and proposal for a new nomenclature. Vox Sang. 1993;64(1):47–55.
   PubMed Web of Science ®Google Scholar
• Zhu HZ, Zhou WJ, Wan YF, et al. Downregulation of orosomucoid 2 acts as a prognostic factor associated with cancer-promoting pathways in liver cancer. World J Gastroenterol. 2020 Feb 28;26(8):804–817.
   PubMed Web of Science ®Google Scholar
• Choi JW, Jeong KH, You JW, et al. Serum levels and glycosylation changes of Alpha-1-acid glycoprotein according to severity of breast cancer in korean women. J Microbiol Biotechnol. 2020 Sep 28;30(9):1297–1304.
   PubMed Web of Science ®Google Scholar
• Gan Y, Li Y, Li T, et al. CCNA2 acts as a novel biomarker in regulating the growth and apoptosis of colorectal cancer. Cancer Manag Res. 2018 Oct 31;10:5113–5124.
   PubMed Web of Science ®Google Scholar
• Shang D, Song B, Liu Y. Epirubicin suppresses proliferative and metastatic potential by downregulating transforming growth factor-β-induced expression in urothelial carcinoma. Cancer Sci. 2018 Apr;109(4):980–987.
   PubMed Web of Science ®Google Scholar
• Khongkow P, Karunarathna U, Khongkow M, et al. FOXM1 targets NBS1 to regulate DNA damage-induced senescence and epirubicin resistance. Oncogene. 2014 Aug 7;33(32):4144–4155.
   PubMed Web of Science ®Google Scholar
• Liu L, Mu LM, Yan Y, et al. The use of functional epirubicin liposomes to induce programmed death in refractory breast cancer. Int J Nanomedicine. 2017 Jun;12(12):4163–4176.
   PubMedGoogle Scholar
• Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN. Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol. 2007;608:1–22.
   PubMed Web of Science ®Google Scholar
• Rekers NH, Troost EG, Zegers CM, et al. Stereotactic ablative body radiotherapy combined with immunotherapy: present status and future perspectives. Cancer Radiother. 2014 Oct;18(5–6):391–395.
   PubMed Web of Science ®Google Scholar
• Khong A, Cleaver AL, Fahmi Alatas M, et al. The efficacy of tumor debulking surgery is improved by adjuvant immunotherapy using imiquimod and anti-CD40. BMC Cancer. 2014 Dec 17;14(1):969.
   PubMedGoogle Scholar
• Dagogo-Jack I, Shaw AT. Tumour heterogeneity and resistance to cancer therapies. Nat Rev Clin Oncol. 2018 Feb;15(2):81–94.
   PubMed Web of Science ®Google Scholar
• Hussain S, Singh A, Nazir SU, et al. Cancer drug resistance: a fleet to conquer. J Cell Biochem. 2019 Sep;120(9):14213–14225.
   PubMed Web of Science ®Google Scholar
• Tatman AJ, Wrigley SR, Jones RM. Resistance to atracurium in a patient with an increase in plasma alpha 1 globulins. Br J Anaesth. 1991 Nov;67(5):623–625.
   PubMed Web of Science ®Google Scholar
• Fink H, Luppa P, Mayer B, et al. Systemic inflammation leads to resistance to atracurium without increasing membrane expression of acetylcholine receptors. Anesthesiology. 2003 Jan;98(1):82–88.
   PubMed Web of Science ®Google Scholar
• Parodi A, Miao J, Soond SM, et al. Albumin nanovectors in cancer therapy and imaging. Biomolecules. 2019 Jun 5;9(6):218.
   PubMed Web of Science ®Google Scholar
• Chassany O, Urien S, Claudepierre P, et al. Comparative serum protein binding of anthracycline derivatives. Cancer Chemother Pharmacol. 1996;38(6):4163–4176.
   Web of Science ®Google Scholar
• Wu DM, Deng SH, Liu T, et al. TGF-β-mediated exosomal lnc-MMP2-2 regulates migration and invasion of lung cancer cells to the vasculature by promoting MMP2 expression. Cancer Med. 2018 Oct;7(10):5118–5129.
   PubMed Web of Science ®Google Scholar
• Zeng F, Yu N, Han Y, et al. The long non-coding RNA MIAT/miR-139-5p/MMP2 axis regulates cell migration and invasion in non-small-cell lung cancer. J Biosci. 2020;45(1):51.
   PubMed Web of Science ®Google Scholar
• Liu X, Shen S, Zhu L, et al. SRSF10 inhibits biogenesis of circ-ATXN1 to regulate glioma angiogenesis via miR-526b-3p/MMP2 pathway. J Exp Clin Cancer Res. 2020 Jun 29;39(1):121.
   PubMed Web of Science ®Google Scholar
• Xu F, Si X, Wang J, et al. Nectin-3 is a new biomarker that mediates the upregulation of MMP2 and MMP9 in ovarian cancer cells. Biomed Pharmacother. 2019 Feb;110:139–144.
   PubMed Web of Science ®Google Scholar
• Song XL, Ju RJ, Xiao Y, et al. Application of multifunctional targeting epirubicin liposomes in the treatment of non-small-cell lung cancer. Int J Nanomedicine. 2017 Oct;12(12):7433–7451.
   PubMedGoogle Scholar
• Zhang F, Wang Z, Fan Y, et al. Elevated STAT3 signaling-mediated upregulation of MMP-2/9 confers enhanced invasion ability in multidrug-resistant breast cancer cells. Int J Mol Sci. 2015 Oct 16;16(10):24772–24790.
   PubMed Web of Science ®Google Scholar
• Revathidevi S, Munirajan AK. Akt in cancer: mediator and more. Semin Cancer Biol. 2019 Dec;59:80–91.
   PubMed Web of Science ®Google Scholar
• Samatar AA, Poulikakos PI. Targeting RAS-ERK signalling in cancer: promises and challenges. Nat Rev Drug Discov. 2014 Dec;13(12):928–942.
   PubMed Web of Science ®Google Scholar
• Degirmenci U, Wang M, Hu J. Targeting Aberrant RAS/RAF/MEK/ERK signaling for cancer therapy. Cells. 2020 Jan 13;9(1):198.
   PubMed Web of Science ®Google Scholar
• Idiiatullina E, Al-Azab M, Walana W, et al. EnDuo, a novel derivative of Endostar, inhibits the migration of colon cancer cells, suppresses matrix metalloproteinase-2/9 expression and impedes AKT/ERK activation. Biomed Pharmacother. 2021 Feb;134:111136.
   PubMed Web of Science ®Google Scholar